For Research Use Only

Thymosin beta 4 Polyclonal antibodyCatalog Number: 19850-1-APFeatured Product18 Publications

proteintech Antibodies | ELISA kits | Proteins www.ptglab.com

Basic Information	Catalog Number: 19850-1-AP	GenBank Accession Numb BC001631	er: Purification Mer Antigen affinity	
	Size:	GeneID (NCBI):		Recommended Dilutions: IP 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate IHC 1:50-1:500 IF-P 1:400-1:1600
	400 μg/ml	7114	-	
	Source: Rabbit	UNIPROT ID: P62328		
	lsotype: IgG	Full Name: thymosin beta 4, X-linked	IF-P 1:400-1:160	
	Immunogen Catalog Number: AG13914	Calculated MW: 63 aa, 7 kDa		
		Observed MW: 5 kDa		
Applications	Tested Applications:	Ро	Positive Controls:	
			mouse skeletal muscle tissue,	
	Cited Applications: WB, IHC, IF		IHC : mouse skeletal muscle tissue, mouse colon tissue	
	Species Specificity: human, mouse, rat	IF-	-P : mouse heart tissue,	
	Cited Species: human, mouse, chicken			
	Note-IHC: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0			
	Thymosin beta 4 (T β 4), encoded by TMSB4X gene, is an actin sequestering protein which plays an important role is the organization of the cytoskeleton. Numerous studies have demonstrated the effects of T β 4 on cell migration, proliferation, apoptosis and inflammation after exogenous treatment (PMID: 22652458). Recently, novel findings provided compelling evidence that T β 4 played a key role in facilitating tumor metastasis and angiogenesis. It has been found that T β 4 expressed increasingly in a number of metastatic tumors, thus providing a potential target of opportunity for cancer management, especially for cancer metastasis therapy (PMID: 22856429).			
Background Information	the organization of the cytoskele proliferation, apoptosis and infla provided compelling evidence th been found that T β 4 expressed in	ton. Numerous studies have dee mmation after exogenous treat at T β 4 played a key role in fac ncreasingly in a number of met	ment (PMID: 22652458). Rec ilitating tumor metastasis a astatic tumors, thus providir	ently, novel findings ind angiogenesis. It h ng a potential target o
	the organization of the cytoskele proliferation, apoptosis and infla provided compelling evidence th been found that T β 4 expressed in	ton. Numerous studies have dee mmation after exogenous treat at T β 4 played a key role in fac ncreasingly in a number of met	ment (PMID: 22652458). Rec ilitating tumor metastasis a astatic tumors, thus providir	ently, novel findings Ind angiogenesis. It h Ig a potential target (129).
	the organization of the cytoskele proliferation, apoptosis and infla provided compelling evidence th been found that T β 4 expressed in opportunity for cancer management	ton. Numerous studies have det mmation after exogenous treat at T β 4 played a key role in fac ncreasingly in a number of met ent, especially for cancer metas	ment (PMID: 22652458). Rec illitating tumor metastasis a astatic tumors, thus providir tasis therapy (PMID: 228564	ently, novel findings Ind angiogenesis. It h ng a potential target o
	the organization of the cytoskele proliferation, apoptosis and infla provided compelling evidence th been found that T β 4 expressed in opportunity for cancer management Author	ton. Numerous studies have det mmation after exogenous treat at T B 4 played a key role in fac ncreasingly in a number of met ent, especially for cancer metas Pubmed ID Journal	ment (PMID: 22652458). Rec illitating tumor metastasis a astatic tumors, thus providir tasis therapy (PMID: 228564 ene Ther	ently, novel findings ind angiogenesis. It h ng a potential target (29). Application
Background Information Notable Publications	the organization of the cytoskele proliferation, apoptosis and infla provided compelling evidence th been found that T β 4 expressed in opportunity for cancer management Author Xiaoyi Zhang	ton. Numerous studies have demmation after exogenous treat at T β 4 played a key role in factor nereasingly in a number of met ent, especially for cancer metas Pubmed ID Journal 36131066 Cancer Ge 34663816 Nat Comm	ment (PMID: 22652458). Rec illitating tumor metastasis a astatic tumors, thus providir tasis therapy (PMID: 228564 ene Ther	ently, novel findings ind angiogenesis. It h ig a potential target of (29). Application IHC,IF


For technical support and original validation data for this product please contact: E: Proteintech-CN@ptglab.com T: 4006900926 W: ptgcn.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.

Selected Validation Data




Immunohistochemical analysis of paraffinembedded mouse skeletal muscle tissue slide using 19850-1-AP (TMSB4X antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




IP result of anti-Thymosin beta 4 (IP:19850-1-AP, 4ug; Detection:19850-1-AP 1:300) with mouse skeletal muscle tissue lysate 4000ug.



Immunohistochemical analysis of paraffinembedded mouse skeletal muscle tissue slide using 19850-1-AP (TMSB4X antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (4% PFA) fixed mouse heart tissue using Thymosin beta 4 antibody (19850-1-AP) at dilution of 1:800 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L).



Immunofluorescent analysis of (4% PFA) fixed mouse heart tissue using Thymosin beta 4 antibody (19850-1-AP) at dilution of 1:800 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L).